louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01990833: Molecular Characteristics of the Persistent Intestinal Fistulae After Glue Application
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Enterocutaneous Fistulas
Lead sponsor: Jinling Hospital, China
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Low-output enterocutaneous fistulas receiving glue application

Brief summary: For non-healing ulcers, abnormal periods of wound healing processes: inflammation, proliferation and remodelling, are believed to lead to chronic wounds. As a chronic "stalled" wound, investigators hypothesized that these glue-assisted closure (GAC)-failed enterocutaneous fistula (ECF) might have a prolonged inflammatory phase modulated by excessive pro-inflammatory cytokines or proteases. The aim of this study was to analyze the chemicals in ECF wounds in order to determine patients' condition and fitness for GAC.


Eligibility criteria: Inclusion Criteria:

* above 18 years old;
* single tubular (tract length \>2 cm) ECF;
* low output volume (\<200 ml/24h);

Exclusion Criteria:

* fistulas of cancer-infiltrated;
* associated abscess;
* foreign bodies;
* distal bowel obstruction;

Primary outcomes:
measure: Fistula closure after glue application
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03067233: Automated Embedded Polysomnography (AEP)
Official title: Automated Embedded Polysomnography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Sponsor class: OTHER
First posted: 2017-03-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: To develop and validate a reliable automatic analysis of the signals recorded during a polysomnography.


Eligibility criteria: Inclusion Criteria:

* Insured by social security
* Speak french

Exclusion Criteria:

* Sleep disorder
* Neurologic, respiratory or cardiac disease

Primary outcomes:
measure: Evaluation of the automatic analysis
timeFrame: 72 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Service des pathologies du sommeil - GH Pitié-Slapêtrière
Study officials:
References:
Clinical trial NCT02075333: The Effect of Ingesting or Rinsing Sucrose and Sucralose on Self-control, Cognitive Performance, and Blood Glucose
Official title: The Effects of Ingesting or Rinsing Sucrose and Sucralose Solutions on Self-control, Cognitive Performance, and Blood Glucose Level
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Self-control
Cognitive Performance
Blood Glucose Response
Lead sponsor: University of Leeds
Sponsor class: OTHER
Collaborators: name: Sugar Nutrition, UK
First posted: 2014-03-03
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to examine the effects of ingesting or mouth rinsing a sucrose (carbohydrate) versus a sucralose (carbohydrate-free) drink on self control, cognitive performance, and blood glucose level.


Eligibility criteria: Inclusion Criteria:

* BMI 18 - 29 kg/m2

Exclusion Criteria:

* Dementia
* Depression
* Type 2 diabetes
* Phenylketonuria
* Intake of medication known to affect glucose metabolism
* Fasting blood glucose \> 7.8 mmol/L

Primary outcomes:
measure: Capillary blood glucose change from baseline following rinsing or ingesting sucrose or sucralose solutions
timeFrame: - 30, -15, - 5, + 5, + 10, + 20, + 30, + 40 minutes relative to rinsing or ingestion of sucrose or sucralose solutions (each separated by 7 days in crossover manner)
Secondary outcomes:
measure: Visual verbal learning and memory performance following self-control depletion
timeFrame: + 35 minutes post ingestion or rinsing of sucrose or sucralose solutions (each separated by 7 days in crossover manner)
measure: Attention switching performance following self-control depletion
timeFrame: + 20 minutes post ingestion or rinsing of sucrose or sucralose solutions (each separated by 7 days in crossover manner)
measure: Continuous blood glucose change from baseline following rinsing or ingesting sucrose or sucralose solutions
timeFrame: 24 hours preceding and during ingestion or rinsing of sucrose or sucralose solutions (each separated by 7 days in a crossover manner)
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: Human Appetite Research Unit (University of Leeds)
Study officials:
affiliation: University of Leeds
name: Neil B Boyle
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Leeds
name: Louise Dye
role: STUDY_CHAIR
References:
Clinical trial NCT04085133: Prevalence and Burden of Bronchiectasis in Tuberculous Patients
Official title: Prevalence and Burden of Bronchiectasis in Tuberculous Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Tuberculoses
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-09-11
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Any tuberculosis patients admited to assuit university hospital and assuit chest hospital

Brief summary: Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree

Detailed description: Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree.

The prevalence of bronchiectasis is age-related and occurs in every age group and in the pre-antibiotic era . it most often began in childhood. Recent evidence shows that bronchiectasis disproportionately affects women and older individuals and will be contributing to increase in healthcare burden.\[3\] International data show an increase in the prevalence of bronchiectasis over recent years.

Eligibility criteria: Inclusion Criteria:

* 1-patients were diagnosed to have tuberculosis by sputum culture and gene x pert.

  2-patients were diagnosed to have bronchiectasis after lab and radiological examination as well as clinical score.

  3- patients diagnosed as bronchiectasis after history of tuberculosis or anti Tuberculosis treatment with positive or negative tuberculous culture in the time of research.

Exclusion Criteria:

* 1-patients presented with other Pulmonary diseases. 2-Chronic liver and renal disease . 3- Lung cancer and tumors. 4- patients were previously diagnosed as bronchiectasis .

Primary outcomes:
measure: To study prevalence of bronchiectasis in TB patients by case per year.
timeFrame: One year
Secondary outcomes:
measure: To evaluate the burden of bronchiectasis in TB patients
timeFrame: one year
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut unviresty
Study officials:
References:
Clinical trial NCT00374387: Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire
Official title: Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Healthy women
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
Collaborators: name: Fund for Scientific Research, Flanders, Belgium
First posted: 2006-09-11
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: 75 heterosexual women are asked to use 3 different types of contraception (Nuvaring, low-dose combination pill, minipill), each during 3 months. On a monthly basis, questionnaires are filled out about sexual desire and psychosocial, relational en sexual parameters. Also the sexual desire of the partner is questioned. On a three-monthly basis, blood samples are drawn to determine changes in hormonal parameters (one sample per product period).

75 lesbian women are doing the same trial, but during an extra 3 months period, they are asked to have their natural menstrual cyclus as a control condition. Blood samples during these extra months will be drawn at the third or fourth day after start of the menses.


Eligibility criteria: Inclusion Criteria:

* Heterosexual or lesbian women
* Aged between 18 and 45 years
* Stable monogameous relationship
* Normal menstrual cyclus

Exclusion Criteria:

* Polycystic ovarial syndrome
* Normal exclusion criteria for the use of contraception
* Use of medication known to influence sexual desire and/or androgen levels
* Women who wants to become pregnant, are pregnant or breastfeeding

Primary outcomes:
measure: Parameters about sexual desire and psychosocial, relational en sexual parameters.
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Petra De Sutter, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00816387: Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle
Official title: Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle: a Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insemination, Artificial
Lead sponsor: IRCCS Burlo Garofolo
Sponsor class: OTHER
First posted: 2009-01-01
Enrollment: 400
Sex: FEMALE
Minimum age (years): 24
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of fallopian sperm perfusion (FSP) in comparison with standard intrauterine insemination (IUI) in natural cycle for couples with unexplained infertility or mild male factor.

Detailed description: A number of randomised controlled trials have been published comparing the efficacy of FSP with standard IUI. A recent meta-analysis has suggested that in couples with unexplained infertility Fallopian tube sperm perfusion together with controlled ovarian hyperstimulation (COH) leads to increased pregnancy rates than IUI and COH. No study has been published comparing the two insemination techniques in natural cycle.

Eligibility criteria: Inclusion Criteria:

* infertility for at least 2 years
* age \<40 years
* unexplained infertility or mild male factor

Exclusion Criteria:

* previous assisted reproduction treatment

Primary outcomes:
measure: clinical pregnancy rate
timeFrame: 2 years
Secondary outcomes:
measure: Abortion rate
timeFrame: 2 years
measure: Ectopic pregnancy rate
timeFrame: 2 years
Other outcomes:
Locations:
city: Trieste
country: Italy
facility: IRCCS Burlo Garofolo
Study officials:
affiliation: IRCCS Burlo Garofolo
name: Giuseppe Ricci, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01301287: The Effect of Chlorella on Glycemic Control of Diabetes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes
Lead sponsor: Cardinal Tien Hospital
Sponsor class: OTHER
Collaborators: name: Tri-Service General Hospital
First posted: 2011-02-23
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chlorella, a type of unicellular fresh water algae, has been a popular foodstuff in Asia, especially in Taiwan. Recent studies have shown the hypoglycemic effects of Chlorella through increasing glucose uptake in the liver and muscle, lowering serum free fatty acid levels, or activation of PPAR gamma receptor. However, the hypoglycemic effect in diabetic patients have not been studied. In order to clarify the hypoglycemic effects and mechanism of Chlorella in diabetic patients, the investigators conducted a 12-week randomized, double-blind, placebo-control trial on diabetic patients.


Eligibility criteria: Inclusion Criteria:

* 18-70 years old
* type 2 diabetes with less than 2 kinds of oral antidiabetes drugs
* Hba1c: 7.0-9.0

Exclusion Criteria:

* type 1 diabetes
* pregnancy
* acute infectious disease
* autoimmune disease
* hemodynamic unstable

Primary outcomes:
measure: HbA1c
timeFrame: 12 weeks
Secondary outcomes:
measure: Insulin concentration during oral glucose tolerance test
timeFrame: 12 weeks
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: Cardinal Tien Hospital
Study officials:
affiliation: Cardinal Tien Hospital 362, Chung Cheng Rd., Hsintien Taipei County 23137 Taiwan R.O.C.
name: Dee Pei, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06719687: Sd-RAB for the Diagnosis of PPLs
Official title: Self-driving Robotic-assisted Bronchoscopy for the Diagnosis of Peripheral Pulmonary Lesions
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Peripheral Pulmonary Lesions
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a single-center, prospective, and single-arm study. The purpose of this study is to evaluate the feasibility and safety of a new self-driving robotic-assisted bronchoscopic system for the diagnosis of peripheral pulmonary lesions.

Detailed description: Self-driving robotic-assisted bronchoscope (Shanghai MicroPort MedBot (Group) Corporation Limited, China) is a new robotic-assisted bronchoscopic system that can automatically advance through airway according to the preoperative planning path under the guidance of electromagnetic navigation. It can also be controlled manually by the operator. In this study, 30 patients will be prospectively enrolled to evaluate the feasibility and safety of this new self-driving robotic-assisted bronchoscopic system for the diagnosis of peripheral pulmonary lesions. The primary endpoint of this study is the complication rate. The secondary endpoints include navigation success rate, diagnostic yield, rate of rEBUS confirmation, total examination time, navigation time, and duration of finding lesions.

Eligibility criteria: Inclusion Criteria:

1. Patients older than 18 years old.
2. Chest imaging shows the presence of peripheral pulmonary lesions (defined as those lesions that are surrounded by pulmonary parenchyma and located below the segmental bronchus), which are suspected to be malignant and require a non-surgical biopsy.
3. Patients have good medical adherence and signed informed consent.

Exclusion Criteria:

1. Contraindications for bronchoscopy.
2. Presence of concomitant endobronchial lesion during the bronchoscopy procedure.
3. The investigators believe that patient has other conditions that are not suitable for the study.

Primary outcomes:
measure: Complication rate
timeFrame: 1 month
Secondary outcomes:
measure: Navigation success rate
timeFrame: 1 month
measure: Diagnostic yield
timeFrame: 1 month
measure: Rate of rEBUS confirmation
timeFrame: During the procedure
measure: Total examination time
timeFrame: During the procedure
measure: Navigation time
timeFrame: During the procedure
measure: Duration of finding lesions
timeFrame: During the procedure
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine
state: Shanghai
Study officials:
affiliation: Shanghai Chest Hospital
name: Jiayuan Sun
role: STUDY_DIRECTOR
References:
Clinical trial NCT03686787: Oral Tranexamic Acid and Laser for Treatment of Melasma
Official title: The Efficacy of Oral Tranexamic Acid and a 1927 nm Diode Laser in Patients With Melasma. A Prospective Randomized Split Face Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Melasma
Keywords: melasma
chloasma
tranexamic acid
nonablative laser resurfacing
sunscreen
hyperpigmentation
Lead sponsor: Laser and Skin Surgery Center of New York
Sponsor class: OTHER
Collaborators: name: Dermatology & Laser Surgery Center, Houston, TX
First posted: 2018-09-27
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Healthy, non-smoking
Primary purpose: TREATMENT

Brief summary: Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

Detailed description: Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of up to $150 will be provided based on completed visits.

Eligibility criteria: Inclusion Criteria:

Age 18 to 50 Skin types I through VI (all skin types) Moderate or severe melasma

Exclusion Criteria:

Pregnant or nursing women Current use of hormonal birth control medication or any hormonal therapy Use of topical steroids within 1 month of study enrollment Use of topical hydroquinone within 3 months of study enrollment History of laser or dermabrasion to the face within 6 months of study enrollment Regular use of tanning parlors Occupation involving primarily outdoor activities Current treatment with blood thinning medications History of thrombosis or thrombophilia History of thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and/or cerebral thrombosis Family history of thromboembolic disease History of stroke History of \>2 spontaneous abortions History of kidney dysfunction History of cancer Smoking Significant cardiovascular or respiratory disease (end-stage congestive heart failure or chronic obstructive pulmonary disease) History of subarachnoid hemorrhage History of acquired disturbances of color vision Known allergy to tranexamic acid As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Primary outcomes:
measure: Change of mMASI (Modified Melasma Area and Severity Index)
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Laser & Skin Surgery Center of New York
state: New York
city: Houston
country: United States
facility: Dermatology & Laser Surgery Center
state: Texas
Study officials:
References:
Clinical trial NCT01788787: Ask Advise Connect (AAC) Harris Heath CPRIT
Official title: Implementation of an Automated EMR System to Connect Smokers in a Safety Net Healthcare System With Smoking Cessation Treatment
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Tobacco Use Cessation
Keywords: Cancer Prevention
Tobacco Use Cessation
Ask Advise Connect
AAC
Smoking Cessation Treatment
Texas Quitline
Saliva sample
Telephone Counseling
Nicotine replacement
Interviews
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Cancer Therapy and Research Center, Texas
First posted: 2013-02-11
Enrollment: 5212
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from the Harris Health System Community Health Clinics

Brief summary: The goal of this behavioral research study is to learn about the outcomes of smoking cessation treatment. Researchers want to learn how many smokers stopped smoking after taking part in smoking cessation treatment with the Texas Quitline.

Detailed description: Study Test:

If you agree to take part in this study, you will collect a saliva sample to test for cotinine to confirm your smoking status. Cotinine is a chemical released in your body when it breaks down nicotine. You will receive a kit in the mail with supplies for the testing. The study staff will call you to make sure that you received the kit and to discuss the instructions with you. To collect the saliva, you will put a small piece of cotton in your mouth for a few minutes. You will mail the saliva sample back to the study staff, using a postage-paid envelope.

Length of Study:

Your participation in this study will be complete after you collect the saliva sample and mail it back to the study staff. Study data will be destroyed 5 years after the study has been completed and the data has been analyzed. Data collected in this study will not be used for future research.

This is an investigational study.

Up to 1,459 participants will be enrolled in this study. All will be enrolled at Harris Health System clinics.

Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older
2. Self-reported current smoker
3. Present for care at one of the 13 Harris Health System (HHS) community clinics
4. Has a working telephone number

Exclusion Criteria:

1) None

Primary outcomes:
measure: Evaluate the Reach of Ask Advise Connect (AAC) Smoking Cessation Program
timeFrame: 2 years
Secondary outcomes:
measure: Efficacy of Ask Advise Connect (AAC) Smoking Cessation Program
timeFrame: 6 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: Harris Health System
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Lorna H. McNeill, PHD, MPH
role: PRINCIPAL_INVESTIGATOR
References: